Xencor (NASDAQ:XNCR) Announces Earnings Results

Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19, Zacks reports. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%.

Xencor Trading Up 2.5 %

Shares of Xencor stock opened at $15.36 on Friday. The stock’s 50-day simple moving average is $19.61 and its 200 day simple moving average is $20.64. Xencor has a 52-week low of $14.18 and a 52-week high of $27.24. The stock has a market capitalization of $1.07 billion, a P/E ratio of -4.80 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Insider Activity

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the sale, the director now directly owns 9,140 shares in the company, valued at $247,054.20. This represents a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.23% of the company’s stock.

Analyst Upgrades and Downgrades

XNCR has been the topic of a number of research analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. JPMorgan Chase & Co. boosted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Wedbush reissued an “outperform” rating and issued a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. Finally, Wells Fargo & Company lowered their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.